Blood Tests for Alzheimer’s Disease: A New Tool for Earlier and Easier Diagnosis
- Team Writer
- 3 hours ago
- 5 min read
Alzheimer's disease is one of the common causes of Dementia, affecting memory, thinking, and behavior. For many years, diagnosing Alzheimer's has been difficult. Doctors typically relied on cognitive tests, medical history, brain scans, or spinal fluid tests to confirm the disease. These methods can be expensive, invasive, or not widely available.
Recently, scientists have developed new blood tests that can help detect Alzheimer's disease more easily. These tests are an important step forward, but they also have some limitations that patients and clinicians should understand.
How the New Blood Tests for Alzheimer's Disease Work
The new blood tests for Alzheimer's disease measure specific proteins linked to the disease. Two of the most important proteins are beta-amyloid and phosphorylated tau (p-tau). In Alzheimer's disease, abnormal amounts of these proteins build up in the brain, forming plaques and tangles that damage brain cells.
Researchers discovered that certain forms of tau, especially p-tau217, can also be detected in the bloodstream. Elevated levels of this protein often indicate that Alzheimer's-related changes are occurring in the brain. Studies show that blood tests measuring p-tau217 can identify Alzheimer's disease with high accuracy and sometimes perform as well as traditional cerebrospinal fluid tests.
In 2025, the U.S. Food and Drug Administration cleared the first blood test designed to assist in diagnosing Alzheimer's disease. The test measures the ratio of p-tau217 to beta-amyloid in a blood sample. This approach allows doctors to detect biological signs of Alzheimer's in people who are already experiencing cognitive symptoms.
How Clinicians Use Blood Tests for Alzheimer's Disease
In most cases, physicians do not use blood tests alone to diagnose Alzheimer's disease. Instead, they are part of a broader evaluation. Doctors still begin with a medical history, neurological exam, and cognitive testing to determine whether a person has memory or thinking problems. If Alzheimer's disease is suspected, a physician may order a blood test to check for disease-related markers.
One important role of the blood test is to help doctors decide whether additional testing is needed. Traditionally, confirming Alzheimer's required PET scans or lumbar punctures (spinal taps). Both methods can be expensive or uncomfortable for patients. Blood tests provide a simpler and less invasive way to screen for evidence of Alzheimer's disease.
In clinical practice today, doctors may use the blood test in several ways:
Screening tool: It can help identify patients who are likely to have Alzheimer's-related changes in the brain.
Confirming suspicion: If cognitive symptoms suggest Alzheimer's, the test can increase a clinician's confidence in the diagnosis.
Selecting patients for treatment: Some newer Alzheimer's medications target amyloid in the brain. Blood tests can help determine which patients might benefit from these treatments.
Research and clinical trials: Researchers are increasingly using blood tests to identify participants for studies of new therapies.
Research shows that adding blood testing to routine evaluations can significantly improve diagnostic accuracy and physician confidence. In some studies, diagnostic accuracy has reached over 90% when blood tests are combined with clinical assessment.
Advantages of Blood Testing
Blood tests offer several benefits compared with older diagnostic methods.
First, they are less invasive. A simple blood draw is easier for patients than a spinal tap, which requires inserting a needle into the lower back to collect cerebrospinal fluid.
Second, blood tests are easier and less expensive than brain imaging tests like PET scans. Many hospitals and clinics already have the equipment needed to perform blood tests, which could make Alzheimer's diagnosis more widely available.
Third, these tests may allow earlier detection of the disease. Some studies suggest that abnormal levels of Alzheimer's-related proteins can appear in the blood years before noticeable memory problems begin.
Earlier detection could help patients and families plan for the future, access support services, and potentially benefit from treatments that work best in the early stages of the disease.
Downsides and Limitations
Despite their promise, blood tests for Alzheimer's disease are not perfect.
One limitation is that the tests are still relatively new. Scientists continue to study how well they work across different populations and healthcare settings. Some research suggests that results may vary by patient group, indicating that additional validation is needed before widespread use.
Another concern is the possibility of false positives or false negatives. A positive test result may suggest Alzheimer's-related changes even when another condition is responsible for the symptoms. Likewise, some people with early Alzheimer's disease might still test negative if protein levels are not yet high enough to be detected.
Blood tests also raise ethical and emotional issues. Learning that someone has biological signs of Alzheimer's—even before symptoms appear—can cause anxiety or uncertainty. Because treatments for Alzheimer's are still limited, some people question whether early testing always benefits patients.
Finally, doctors emphasize that these tests should not replace a full clinical evaluation. Memory problems can have many causes, including depression, medication side effects, sleep disorders, or other neurological diseases.
The Future of Alzheimer's Diagnosis
Blood tests for Alzheimer's disease represent one of the most exciting advances in Dementia research in recent years. By providing a simpler and more accessible way to detect disease-related changes, they could help doctors diagnose Alzheimer's earlier and more accurately.
However, experts stress that these tests are just one part of the diagnostic process. Continued research will help refine their use, determine the best cutoff values for test results, and clarify how testing should guide treatment decisions.
As researchers develop new treatments and prevention strategies, blood tests may become an increasingly important tool in the fight against Alzheimer's disease—helping clinicians identify the disease earlier and improving care for millions of patients and families.
Additional Reading:
Wisch JK and Ances BM. Ruling in, ruling out: the clinical utility of plasma biomarkers in diagnosis of Alzheimer's disease. J Clinical Investigation October 1, 2025.
Ashton NJ et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer's disease pathology. J American Medical Association Neurology: January 22, 2024.
Disclaimer: Dementia Society of America (DSA) provides educational content only and does not offer medical advice. Always consult a qualified healthcare professional before making changes to your medical care. DSA content is created by both human and computer-generated means and is reviewed for accuracy; however, errors may occur. Views expressed by third-party contributors do not necessarily reflect those of DSA. Unless expressly stated, DSA does not endorse or guarantee any third-party products, services, organizations, or external content. All DSA content is copyrighted and/or trademarked and may not be used without written permission.
Comments